Meiji Seika Pharma Launches Phase I Trial of ME3241, Novel PD-1 Agonist for Autoimmune Diseases
核心洞察
Meiji Seika Pharma (搜索) has initiated a Phase I clinical trial in Australia for ME3241 (搜索), an anti-PD-1 (搜索) agonist monoclonal antibody designed to treat autoimmune diseases (搜索) by enhancing immune suppression.
The drug represents a therapeutic approach opposite to cancer immunotherapy, stimulating rather than blocking PD-1 (搜索) to reduce excessive immune responses in inflammatory conditions.
ME3241 (搜索) was discovered through collaboration with Nobel laureate Tasuku Honjo and the Foundation for Biomedical Research and Innovation at Kobe (搜索), with foundational research published in Science Immunology.
Meiji Seika Pharma (搜索) Co., Ltd. announced the initiation of a Phase I clinical trial for ME3241 (搜索), a novel anti-PD-1 (搜索) agonist monoclonal antibody targeting autoimmune diseases (搜索). The randomized, placebo-controlled, double-blind study launched in Australia will evaluate the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics.
Revolutionary Approach to PD-1 Targeting
ME3241 (搜索) represents a paradigm shift in PD-1 (搜索)-targeted therapy, taking the opposite approach to widely used cancer immunotherapies. While cancer treatments employ PD-1 antagonist antibodies to enhance immune responses against tumors, ME3241 functions as a PD-1 agonist, stimulating the pathway to suppress excessive immune activity in autoimmune conditions.
The drug was discovered through collaborative research led by Program Director Tasuku Honjo, professor emeritus at Kyoto University and Nobel laureate, in partnership with the Foundation for Biomedical Research and Innovation at Kobe (搜索) (FBRI). PD-1 (搜索) is a molecule expressed on activated T cells and other lymphocytes that naturally suppresses immune responses.
Scientific Foundation and Development
Through their research collaboration, Meiji Seika Pharma (搜索) and FBRI identified the specific conditions required to induce immunosuppression by stimulating PD-1 (搜索) with antibodies. These groundbreaking findings were published in Science Immunology on January 13, 2023, establishing the scientific foundation for ME3241 (搜索)'s development.
ME3241 (搜索) is characterized as a unique anti-PD-1 (搜索) agonist antibody with enhanced PD-1 agonist activity, positioning it as a potential therapeutic agent for inflammatory diseases (搜索), including autoimmune diseases (搜索) caused by excessive immune responses.
Clinical Trial Design and Objectives
The Phase I study, registered as NCT07422207 on ClinicalTrials.gov, is designed to comprehensively evaluate ME3241 (搜索)'s clinical profile in human subjects. The trial will assess safety and tolerability parameters while gathering crucial pharmacokinetic and pharmacodynamic data to inform future development phases.
"The initiation of the Phase I clinical trial of an autoimmune disease therapy by a PD-1 (搜索) agonist antibody is highly significant, as our finding marks a major milestone in taking a step toward potential therapeutic application for human disease," stated Tasuku Honjo, Program Director and Honorary President of FBRI.
Development Timeline and Expectations
Honjo emphasized the significance of reaching clinical testing after achieving robust results in animal models. "Should safety be confirmed in Phase I, there is strong expectation that the program will progress to Phase II to evaluate efficacy, and subsequently to Phase III with the aim of practical implementation," he noted.
The therapeutic approach originated from basic research initiated shortly after Honjo's appointment as director, representing years of foundational work now transitioning to clinical application.
Strategic Collaboration and Future Plans
Takeshi Naruse, Senior Managing Executive Officer and Head of Research & Development at Meiji Seika Pharma (搜索), highlighted the strategic importance of the collaboration. "We have been advancing collaborative research with Professor Tasuku Honjo to discover and develop new drug candidates for inflammatory diseases (搜索), an area closely related to Meiji Seika Pharma's focus on infectious diseases," Naruse stated.
The companies plan to continue their collaboration to advance ME3241 (搜索)'s development, with both organizations committed to delivering the therapy to patients with autoimmune diseases (搜索) as quickly as possible. Meiji Seika Pharma (搜索) and FBRI will work together to expedite the development process and provide meaningful benefits to patients with autoimmune diseases at the earliest opportunity.